プロラクチノーマの治療計画

出典
imgimg
1: Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas.
著者: Felipe F Casanueva, Mark E Molitch, Janet A Schlechte, Roger Abs, Vivien Bonert, Marcello D Bronstein, Thierry Brue, Paolo Cappabianca, Annamaria Colao, Rudolf Fahlbusch, Hugo Fideleff, Moshe Hadani, Paul Kelly, David Kleinberg, Edward Laws, Josef Marek, Maurice Scanlon, Luis G Sobrinho, John A H Wass, Andrea Giustina
雑誌名: Clin Endocrinol (Oxf). 2006 Aug;65(2):265-73. doi: 10.1111/j.1365-2265.2006.02562.x.
Abstract/Text: In June 2005, an ad hoc Expert Committee formed by the Pituitary Society convened during the 9th International Pituitary Congress in San Diego, California. Members of this committee consisted of invited international experts in the field, and included endocrinologists and neurosurgeons with recognized expertise in the management of prolactinomas. Discussions were held that included all interested participants to the Congress and resulted in formulation of these guidelines, which represent the current recommendations on the diagnosis and management of prolactinomas based upon comprehensive analysis and synthesis of all available data.
Clin Endocrinol (Oxf). 2006 Aug;65(2):265-73. doi: 10.1111/j.1365-2265...

高プロラクチン血症の原因

[ID0602]　高プロラクチン血症を起こす薬剤
出典
imgimg
1: Guidelines for the diagnosis and treatment of hyperprolactinemia.
著者: B M Biller, A Luciano, P G Crosignani, M Molitch, D Olive, R Rebar, J Sanfilippo, J Webster, H Zacur
雑誌名: J Reprod Med. 1999 Dec;44(12 Suppl):1075-84.
Abstract/Text: Hyperprolactinemia is the most common endocrine disorder of the hypothalamic-pituitary axis. While it can occur in men, it occurs more commonly in women. The prevalence of hyperprolactinemia ranges from 0.4% in an unselected normal adult population to as high as 9-17% in women with reproductive disorders. There are many possible causes of hyperprolactinemia, falling into three general categories: physiologic, pharmacologic and pathologic. When specific treatable underlying causes have been eliminated and in cases of severe hyperprolactinemia, the most likely cause is a prolactin (PRL)-secreting pituitary adenoma. Microadenomas should be treated medically, with a dopamine agonist, if there is an indication for therapy (such as amenorrhea, infertility or bothersome galactorrhea). If there is no indication for therapy, microadenomas may be followed conservatively, as growth is uncommon. Macroadenomas may grow larger; medical therapy is recommended initially, with neurosurgical evaluation reserved for specific clinical situations, such as failure of medical therapy and evidence of mass effect despite medical therapy. In the United States, the dopamine agonists indicated for treatment of hyperprolactinemia are bromocriptine and cabergoline. Bromocriptine is usually given once or twice daily, while cabergoline has a long duration of action and is given once or twice weekly. Results of comparative studies indicate that cabergoline is clearly superior to bromocriptine in efficacy (PRL suppression, restoration of gonadal function) and tolerability.
J Reprod Med. 1999 Dec;44(12 Suppl):1075-84.

高プロラクチン血症を起こす薬剤

出典
imgimg
1: Guidelines for the diagnosis and treatment of hyperprolactinemia.
著者: B M Biller, A Luciano, P G Crosignani, M Molitch, D Olive, R Rebar, J Sanfilippo, J Webster, H Zacur
雑誌名: J Reprod Med. 1999 Dec;44(12 Suppl):1075-84.
Abstract/Text: Hyperprolactinemia is the most common endocrine disorder of the hypothalamic-pituitary axis. While it can occur in men, it occurs more commonly in women. The prevalence of hyperprolactinemia ranges from 0.4% in an unselected normal adult population to as high as 9-17% in women with reproductive disorders. There are many possible causes of hyperprolactinemia, falling into three general categories: physiologic, pharmacologic and pathologic. When specific treatable underlying causes have been eliminated and in cases of severe hyperprolactinemia, the most likely cause is a prolactin (PRL)-secreting pituitary adenoma. Microadenomas should be treated medically, with a dopamine agonist, if there is an indication for therapy (such as amenorrhea, infertility or bothersome galactorrhea). If there is no indication for therapy, microadenomas may be followed conservatively, as growth is uncommon. Macroadenomas may grow larger; medical therapy is recommended initially, with neurosurgical evaluation reserved for specific clinical situations, such as failure of medical therapy and evidence of mass effect despite medical therapy. In the United States, the dopamine agonists indicated for treatment of hyperprolactinemia are bromocriptine and cabergoline. Bromocriptine is usually given once or twice daily, while cabergoline has a long duration of action and is given once or twice weekly. Results of comparative studies indicate that cabergoline is clearly superior to bromocriptine in efficacy (PRL suppression, restoration of gonadal function) and tolerability.
J Reprod Med. 1999 Dec;44(12 Suppl):1075-84.

高プロラクチン血症の診断手順

出典
imgimg
1: Guidelines for the diagnosis and treatment of hyperprolactinemia.
著者: B M Biller, A Luciano, P G Crosignani, M Molitch, D Olive, R Rebar, J Sanfilippo, J Webster, H Zacur
雑誌名: J Reprod Med. 1999 Dec;44(12 Suppl):1075-84.
Abstract/Text: Hyperprolactinemia is the most common endocrine disorder of the hypothalamic-pituitary axis. While it can occur in men, it occurs more commonly in women. The prevalence of hyperprolactinemia ranges from 0.4% in an unselected normal adult population to as high as 9-17% in women with reproductive disorders. There are many possible causes of hyperprolactinemia, falling into three general categories: physiologic, pharmacologic and pathologic. When specific treatable underlying causes have been eliminated and in cases of severe hyperprolactinemia, the most likely cause is a prolactin (PRL)-secreting pituitary adenoma. Microadenomas should be treated medically, with a dopamine agonist, if there is an indication for therapy (such as amenorrhea, infertility or bothersome galactorrhea). If there is no indication for therapy, microadenomas may be followed conservatively, as growth is uncommon. Macroadenomas may grow larger; medical therapy is recommended initially, with neurosurgical evaluation reserved for specific clinical situations, such as failure of medical therapy and evidence of mass effect despite medical therapy. In the United States, the dopamine agonists indicated for treatment of hyperprolactinemia are bromocriptine and cabergoline. Bromocriptine is usually given once or twice daily, while cabergoline has a long duration of action and is given once or twice weekly. Results of comparative studies indicate that cabergoline is clearly superior to bromocriptine in efficacy (PRL suppression, restoration of gonadal function) and tolerability.
J Reprod Med. 1999 Dec;44(12 Suppl):1075-84.

高プロラクチン血症の治療計画

出典
imgimg
1: Guidelines for the diagnosis and treatment of hyperprolactinemia.
著者: B M Biller, A Luciano, P G Crosignani, M Molitch, D Olive, R Rebar, J Sanfilippo, J Webster, H Zacur
雑誌名: J Reprod Med. 1999 Dec;44(12 Suppl):1075-84.
Abstract/Text: Hyperprolactinemia is the most common endocrine disorder of the hypothalamic-pituitary axis. While it can occur in men, it occurs more commonly in women. The prevalence of hyperprolactinemia ranges from 0.4% in an unselected normal adult population to as high as 9-17% in women with reproductive disorders. There are many possible causes of hyperprolactinemia, falling into three general categories: physiologic, pharmacologic and pathologic. When specific treatable underlying causes have been eliminated and in cases of severe hyperprolactinemia, the most likely cause is a prolactin (PRL)-secreting pituitary adenoma. Microadenomas should be treated medically, with a dopamine agonist, if there is an indication for therapy (such as amenorrhea, infertility or bothersome galactorrhea). If there is no indication for therapy, microadenomas may be followed conservatively, as growth is uncommon. Macroadenomas may grow larger; medical therapy is recommended initially, with neurosurgical evaluation reserved for specific clinical situations, such as failure of medical therapy and evidence of mass effect despite medical therapy. In the United States, the dopamine agonists indicated for treatment of hyperprolactinemia are bromocriptine and cabergoline. Bromocriptine is usually given once or twice daily, while cabergoline has a long duration of action and is given once or twice weekly. Results of comparative studies indicate that cabergoline is clearly superior to bromocriptine in efficacy (PRL suppression, restoration of gonadal function) and tolerability.
J Reprod Med. 1999 Dec;44(12 Suppl):1075-84.

プロラクチノーマの治療計画

出典
imgimg
1: Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas.
著者: Felipe F Casanueva, Mark E Molitch, Janet A Schlechte, Roger Abs, Vivien Bonert, Marcello D Bronstein, Thierry Brue, Paolo Cappabianca, Annamaria Colao, Rudolf Fahlbusch, Hugo Fideleff, Moshe Hadani, Paul Kelly, David Kleinberg, Edward Laws, Josef Marek, Maurice Scanlon, Luis G Sobrinho, John A H Wass, Andrea Giustina
雑誌名: Clin Endocrinol (Oxf). 2006 Aug;65(2):265-73. doi: 10.1111/j.1365-2265.2006.02562.x.
Abstract/Text: In June 2005, an ad hoc Expert Committee formed by the Pituitary Society convened during the 9th International Pituitary Congress in San Diego, California. Members of this committee consisted of invited international experts in the field, and included endocrinologists and neurosurgeons with recognized expertise in the management of prolactinomas. Discussions were held that included all interested participants to the Congress and resulted in formulation of these guidelines, which represent the current recommendations on the diagnosis and management of prolactinomas based upon comprehensive analysis and synthesis of all available data.
Clin Endocrinol (Oxf). 2006 Aug;65(2):265-73. doi: 10.1111/j.1365-2265...

高プロラクチン血症の原因

[ID0602]　高プロラクチン血症を起こす薬剤
出典
imgimg
1: Guidelines for the diagnosis and treatment of hyperprolactinemia.
著者: B M Biller, A Luciano, P G Crosignani, M Molitch, D Olive, R Rebar, J Sanfilippo, J Webster, H Zacur
雑誌名: J Reprod Med. 1999 Dec;44(12 Suppl):1075-84.
Abstract/Text: Hyperprolactinemia is the most common endocrine disorder of the hypothalamic-pituitary axis. While it can occur in men, it occurs more commonly in women. The prevalence of hyperprolactinemia ranges from 0.4% in an unselected normal adult population to as high as 9-17% in women with reproductive disorders. There are many possible causes of hyperprolactinemia, falling into three general categories: physiologic, pharmacologic and pathologic. When specific treatable underlying causes have been eliminated and in cases of severe hyperprolactinemia, the most likely cause is a prolactin (PRL)-secreting pituitary adenoma. Microadenomas should be treated medically, with a dopamine agonist, if there is an indication for therapy (such as amenorrhea, infertility or bothersome galactorrhea). If there is no indication for therapy, microadenomas may be followed conservatively, as growth is uncommon. Macroadenomas may grow larger; medical therapy is recommended initially, with neurosurgical evaluation reserved for specific clinical situations, such as failure of medical therapy and evidence of mass effect despite medical therapy. In the United States, the dopamine agonists indicated for treatment of hyperprolactinemia are bromocriptine and cabergoline. Bromocriptine is usually given once or twice daily, while cabergoline has a long duration of action and is given once or twice weekly. Results of comparative studies indicate that cabergoline is clearly superior to bromocriptine in efficacy (PRL suppression, restoration of gonadal function) and tolerability.
J Reprod Med. 1999 Dec;44(12 Suppl):1075-84.